Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

Masayuki Umemura; Hitoshi Nishimura; Kimika Saito; Toshiki Yajima; Goro Matsuzaki; Satoru Mizuno; Isamu Sugawara; Yasunobu Yoshikai

doi:10.1128/IAI.71.10.6045-6048.2003

Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination

Infect Immun. 2003 Oct;71(10):6045-8. doi: 10.1128/IAI.71.10.6045-6048.2003.

Authors

Masayuki Umemura¹, Hitoshi Nishimura, Kimika Saito, Toshiki Yajima, Goro Matsuzaki, Satoru Mizuno, Isamu Sugawara, Yasunobu Yoshikai

Affiliation

¹ Molecular Microbiology Group, Center of Molecular Biosciences, University of the Ryukyus, Okinawa 903-0213, Japan.

Abstract

Interleukin-15 (IL-15) transgenic mice which had been inoculated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) 24 weeks previously showed resistance against airborne infection with Mycobacterium tuberculosis H37Rv accompanied by an increased CD8(+)-Tc1-cell response. IL-15 may be used as an immune adjuvant given with BCG vaccination to enhance its biologic efficacy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Animals
Antigens, Bacterial
BCG Vaccine / administration & dosage*
CD4-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / immunology
Female
Immunologic Memory
Interferon-gamma / biosynthesis
Interleukin-15 / administration & dosage*
Interleukin-15 / genetics
Interleukin-15 / physiology*
Male
Mice
Mice, Inbred C57BL
Mice, Transgenic
Mycobacterium bovis / immunology
Mycobacterium tuberculosis / immunology
Tuberculosis / immunology
Tuberculosis / prevention & control

Substances

Adjuvants, Immunologic
Antigens, Bacterial
BCG Vaccine
Interleukin-15
Interferon-gamma